Introduction
============

Nasopharyngeal carcinoma (NPC) is a malignant tumor that originates in the upper lining epithelium of the human retronasal cavity.[@b1-ott-7-457] It is generally rare, but is more common in certain geographic regions, such as Southeast Asia, North Africa, and especially Southern China.[@b2-ott-7-457] The annual incidence of NPC is up to 30 per 100,000 in Guangdong (a province in Southern China), which is 50-fold higher than that in the Western world.[@b3-ott-7-457] There is a clear relationship between NPC and this specific region, with convincing evidence of a correlation with Epstein--Barr virus (EBV) infection.[@b4-ott-7-457] Although this tumor is sensitive to radiotherapy, therapy can fail in patients with advanced stage disease, as the disease is highly invasive and metastatic in nature.[@b5-ott-7-457],[@b6-ott-7-457]

Because of the significant correlation between NPC and EBV, most studies of NPC have focused on EBV-related proteins and genes, such as EBER (EBV-encoded RNA) and LMP (EBV-associated membrane antigen).[@b7-ott-7-457],[@b8-ott-7-457] Gene linkage studies have also been conducted.[@b9-ott-7-457] Moreover, several chromosome regions, such as 3p21.3-1-21.2, and the human leukocyte antigen (HLA) haplotypes have been linked to the development of NPC.[@b10-ott-7-457]--[@b12-ott-7-457] Previous studies have also investigated the expression of other genes, such as *TP53* in NPC.[@b13-ott-7-457]--[@b16-ott-7-457] *C-KIT* and *PIK3CA* mutations have been detected in NPC cell lines and NPC specimens.[@b17-ott-7-457],[@b18-ott-7-457] However, few studies have examined the genomic mutations of NPC.

Matrix-assisted laser desorption ionization--time of flight mass spectrometry (MALDI-TOF MS) can detect multiple gene mutations with high sensitivity and accuracy. Using this technology, Patrick et al showed that *RAS* mutations are more frequent in cutaneous squamous cell tumor patients treated with *RAF* inhibitors than in those not so treated.[@b19-ott-7-457] Kang et al also detected *EGFR* T790M mutations in patients with non-small-cell lung cancer using MALDI-TOF MS, which detected and quantified the mutations highly sensitively.[@b20-ott-7-457] In this study, a panel of 19 oncogenes including *EGFR*, *RAS* family genes, *KIT*, and *PIK3CA*, were analyzed for 238 possible mutations in tumor tissues from 123 NPC patients. The purpose of this study was to analyze the mutational status of multiple genes in NPC samples and clarify the possible relationships between these mutations and the characteristics of NPC patients.

Materials and methods
=====================

Clinical samples
----------------

Formalin-fixed paraffin-embedded samples were obtained from 123 patients with pathologically diagnosed NPC between October 1991 and July 2002 at Sun Yat-sen University Cancer Center (SYSUCC) (Guangzhou, People's Republic of China). Informed consent and clinicopathological information were obtained from all patients. Disease stage was classified or reclassified according to the People's Republic of China 1992 NPC TNM staging system.[@b21-ott-7-457] The clinicopathological characteristics of the 123 NPC patients are summarized in [Table 1](#t1-ott-7-457){ref-type="table"}. Institute Research Medical Ethics Committee of SYSUCC granted approval for this study.

DNA extraction
--------------

We chose paraffin blocks containing more than 60% tumor cells from hematoxylin and eosin stained sections of each tumor. Sections (4--6 μm) were cut and transferred to 1.5 mL Eppendorf tubes for DNA extraction. DNA was extracted using the QIAamp DNA Formalin-fixed Paraffin-embedded Tissue Kit (Qiagen, Hilden, Germany), according to the manufacturer's protocol. The quantity and quality of the isolated DNA were tested using a Nanodrop ND-2000 Spectrophotometer (Thermo Scientific, Niederelbert, Germany). The final DNA samples were diluted to 10 ng/μL for analysis.

OncoCarta assay
---------------

A total of 238 possible mutations in 19 oncogenes were investigated in 123 NPC samples using the OncoCarta Panel (v 1.0; Sequenom Inc., San Diego, CA, USA). This panel is a set of predesigned and prevalidated assays for sensitive and efficient mutation screening by the parallel analysis of 238 possible mutations across the following 19 common oncogenes: *ABL1*, *AKT1*, *AKT2*, *BRAF*, *CDK*, *EGFR*, *ERBB2*, *FGFR1*, *FGFR3*, *FLT3*, *HRAS*, *JAK2*, *KIT*, *KRAS*, *MET*, *NRAS*, *PDGFRA*, *PIK3CA*, and *RET*. The mutation types of each gene are list in [Table S1](#SD2-ott-7-457){ref-type="supplementary-material"}.

In brief, 20 ng of DNA was amplified using 24 sets of OncoCarta PCR primers. An extension reaction based on the OncoCarta extension primers was then performed. After a cation exchange resin was used to remove salts, the products were spotted onto a 384-well SpectroChipII using the MassARRAY Nanodispenser RS1000 (Sequenom Inc.) and analyzed on a MALDI-TOF mass spectrometer (Sequenom Inc.). We chose high performance liquid chromatography purified water as the blank control and normal human somatic cells as the negative control in each experiment.

Data analysis
-------------

Mutation data was analyzed using the software MassARRAY Typer (v4.0; Sequenom Inc.), using a cutoff mutation frequency of 1%. A successful experiment should show that the sample figure was typical and the blank control had no peak ([Figure 1](#f1-ott-7-457){ref-type="fig"}).

Statistical analysis
--------------------

The statistical analysis was performed using SPSS software (v 16.0; SPSS Inc., Chicago, IL, USA). The relationships between the patients' mutational status and clinical data were assessed with a *χ^2^* or Fisher's exact test. Kaplan--Meier analysis was used to compare differences in the survival rate of the groups. A *P*-value of less than 0.05 was considered statistically significant. A multivariate analysis was used to check the possible relationship between factors. Overall survival (OS) and progression-free survival (PFS) were calculated for the 123 NPC patients from the date of surgery until death or the last follow-up. The clinical data follow-up date was updated to October 2012.

Results
=======

Mutation profiles of NPC tumors
-------------------------------

Mutations were detected in 17.1% (21/123) of NPC tumors, with one NPC patient having two simultaneous mutations. Therefore, a total of 21 patients presented with 22 mutations. The mutations affected eight oncogenes, as follows: six in *PIK3CA* (three E542K, two H1047Y, and one R38H), five in *NRAS* (one G12D, two G13D, and two Q61K), four in *KIT* (two V559I, one V559A, and one D52N), two in *PDGFRA* (two T647I), and two in *ABL* (two E255K); *HRAS* (G13S) and *EGFR* (E709A) mutations were found in one NPC tumor each; one NPC tumor had a *BRAF* mutation (G464E) together with a *PIK3CA* mutation (E545K). No mutation was detected in the remaining 102 (82.9%) NPC tissues (with no mutations in *AKT1*, *AKT2*, *CDK*, *ERBB2*, *FGFR1*, *FGFR3*, *FLT3*, *JAK2*, *KRAS*, *MET*, or *RET*). The mutational profiles and distributions of the NPC tumors are shown in [Table 2](#t2-ott-7-457){ref-type="table"}.

Correlations between oncogene mutations and patient clinicopathological characteristics
---------------------------------------------------------------------------------------

We divided the patients into groups according to their clinical characteristics, and calculated the mutation rate in each group. We then assessed the relationships between the mutational status and clinical data using the *χ^2^* or Fisher's exact test. The results are presented in [Table 3](#t3-ott-7-457){ref-type="table"}. There was an association between oncogene mutations and relapse/metastasis of NPC (*P*=0.019, [Table 3](#t3-ott-7-457){ref-type="table"}). We also tested the intersubject effects with a univariate analysis and found no effect between all factors ([Table S2](#SD3-ott-7-457){ref-type="supplementary-material"}). No significant correlation between the presence of an oncogenic mutation and other clinicopathological parameters, such as age, sex, clinical stage, or WHO histological grade was found (*P*\>0.05, [Table 3](#t3-ott-7-457){ref-type="table"}).

Correlation between oncogene mutation and patient survival
----------------------------------------------------------

We estimated the survival of NPC patients by comparing the OS and PFS of the mutation and wild-type subgroups ([Figure 2](#f2-ott-7-457){ref-type="fig"}). The mean survival time (MST) in the mutation subgroup did not differ significantly from that of the wild-type subgroup (OS: 86.5 vs 90.0, *P*\>0.05, [Figure 2A](#f2-ott-7-457){ref-type="fig"}; PFS: 83.6 vs 88.6, *P*\>0.05, [Figure 2B](#f2-ott-7-457){ref-type="fig"}).

Because the *PIK3CA*, *KIT*, and *NRAS* oncogenes had higher mutation frequencies of the oncogenes analyzed, we also assessed the correlation between the clinicopathological characteristics of the patients and the presence of these mutations, but found no significant correlation ([Table S3](#SD4-ott-7-457){ref-type="supplementary-material"}).

Discussion
==========

Various aspects of NPC have been widely investigated because it is an important cancer of the head and neck. However, few studies have examined the role of mutations in NPC, and the results of such studies are controversial. In this study, our data show that *PIK3CA*, *KIT*, and *RAS* are the oncogenes most susceptible to mutations in NPC, whereas mutations of *BRAF*, *PDGFRA*, *ABL1*, and *EGFR* occur less frequently. Many of the mutations described here have never been previously reported in NPC samples. A summary of oncogenes' mutations in NPC in our study and other literature is shown in [Table 4](#t4-ott-7-457){ref-type="table"}.[@b17-ott-7-457],[@b18-ott-7-457],[@b22-ott-7-457]--[@b33-ott-7-457]

In a comparison of the mutation frequencies in the subgroups of patients with and without relapse or metastasis, we found that NPC patients who relapsed or developed metastases had higher mutation frequencies (28.9% vs 11.8%, respectively, *P*=0.019).

The *PIK3CA* gene encodes the p110α catalytic subunit of PI3K and plays an important role in many tumors. Mutations of this gene are reportedly located in exons 9 and 20, with hotspots at E542K, E545K, and H1047Y.[@b34-ott-7-457] In our study, 83.3% (5/6) of all the *PIK3CA* mutations identified occurred at these hotspots. We found that NPC patient survival did not correlate significantly with the presence of *PIK3CA* mutations, which is consistent with a previous study ([Figure S1](#SD1-ott-7-457){ref-type="supplementary-material"}).[@b33-ott-7-457] In NPC cell lines, the inhibitor NVP-BEZ235 was found to selectively inhibit the proliferation of NPC cells carrying *PIK3CA* mutations.[@b35-ott-7-457] Currently, mTOR inhibitors are used as therapies for cancers in which the PI3K/AKT/mTOR pathway is activated. Although mutation rate is not so high, PIK3CA is also worthy as a research object of targeted therapy in NPC.

It is well established that the RAS/RAF/ERK pathway plays an important role in tumor development. *KRAS*, *HRAS*, and *NRAS* mutations occur in at least one-third of all human cancers, with *KRAS* mutations being the most common.[@b28-ott-7-457],[@b36-ott-7-457],[@b37-ott-7-457] In the present study, we detected mutations of *NRAS* and *HRAS*, but not in *KRAS. KRAS* mutation rate in all tumors is estimated to be 25%--30%.[@b38-ott-7-457] But here, in NPC, *KRAS* mutation is particularly scarce. We detected *NRAS* mutations at Q61K, G13D, and G12D and a *HRAS* mutation at G13S, all of which are acknowledged hotspots. Consistent with our results, previous studies have detected no mutations in codons 12, 13, or 61 of *KRAS* in NPC specimens or NPC cell lines.[@b28-ott-7-457],[@b33-ott-7-457] These data suggest that *RAS* mutations exist in NPC, but that *KRAS* mutations are rare.

*KIT* is a type III receptor tyrosine kinase that initiates multiple downstream signaling pathways, such as the PI3K/AKT and JAK/STAT pathways. *KIT* gene mutations are mainly found in melanomas, and imatinib is an effective inhibitor of this oncogene. Here, we observed mutations V559I and V559A, which are the most common *KIT* mutation types. V559I is considered to confer resistance to imatinib, whereas V559A reportedly confers sensitivity to imatinib.[@b39-ott-7-457],[@b40-ott-7-457] PDGFRA belongs to the type III tyrosine kinase family. In fact, there appears to be a close relationship between *KIT* and *PDGFRA*, and the correlation between them has been widely investigated.[@b41-ott-7-457],[@b42-ott-7-457] *PDGFRA* mutation T674I confers imatinib resistance. In the present study, both mutations of *KIT* (3.3%) and *PDGFR* (1.6%) were detected in NPC tissues; this result is consistent with other reports.[@b43-ott-7-457],[@b44-ott-7-457] Further clinical trials are required to evaluate the correlation between NPC patients with *KIT* and *PDGFR* mutations and their response to the drug imatinib.

*EGFR* is a cell-surface protein that binds to EGF, and mutations in *EGFR* are associated with a wide variety of tumors. *EGFR* mutations are very frequent in non-small-cell lung cancer, with exons 18, 19, 20, and 21 being the predominantly mutated regions.[@b45-ott-7-457] In our study, only one NPC patient was positive for an *EGFR* mutation, resulting in a mutation rate of less than 1%. This mutation was E709A, which is encoded in exon 20 and usually reported in lung cancer.[@b46-ott-7-457],[@b47-ott-7-457] This result may suggest that the treatment of NPC patients with tyrosine kinase inhibitors may not be an effective strategy.

Detection of multiple mutations status in NPC was also one of our aims. It can provide more information about treatment and prognosis than single mutation detection. Herein, one NPC sample was detected to have two simultaneous mutations (*PIK3CA* and *BRAF*). Studies have suggested that the concurrent presence of *PIK3CA* and *BRAF* mutations predict resistance to everolimus.[@b48-ott-7-457],[@b49-ott-7-457]

We should not ignore the negative results of this study. This report describes the analysis of 238 potential mutations in 19 oncogenes in 123 NPC samples to gain a preliminary understanding of mutational status of these 19 oncogenes. The negative results of this study indicate that mutations are rare in *NPC*, *AKT1*, *AKT2*, *CDK*, *ERBB2*, *FGFR1*, *FGFR3*, *FLT3*, *JAK2*, *KRAS*, *MET*, and *RET*, suggesting that drugs targeting these genes may be ineffective.

This study had several limitations. Compared with deep sequencing, MALDI-TOF MS offers high-throughput and is less expensive. However, the comprehensiveness of detection is inadequate. Many deserted or concealed mutations cannot be detected using this method, so we may miss some important genes in NPC.

Conclusion
==========

In summary, a small number of mutations in *NRAS, KIT, PIK3CA, PDGFRA,* and *ABL* are present in NPC, whereas mutations in other genes, including *AKT1, AKT2, CDK, ERBB2, FGFR1, FGFR3, FLT3, JAK2, KRAS, MET*, and *RET*, are extremely rare. The presence of oncogene mutations in NPC patients is associated with relapse and metastasis.

Supplementary materials
=======================

###### 

Kaplan--Meier survival curves for NPC patients classified as either with or without PIK3CA mutations. (**A**) Overall survival (OS) curve of NPC patients with PIK3CA mutations have no difference in wild-type NPC patients; (**B**) progression-free survival (PFS) curve of NPC patients with PIK3CA mutations also have no difference in wild-type NPC patients.

**Abbreviation:** NPC, nasopharyngeal carcinoma.

###### 

Mutation subtypes detected by the OncoCarta Panel (v 1.0; Sequenom Inc., San Diego, CA, USA) MassARRAY

  Gene       Mutation subtypes
  ---------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *ABL1*     G250E; F317L; M351T; E355G; F359V; H396R; Q252H; Y253H; Y253F; E255K; E255V; D276G; F311L; T315I
  *AKT1*     rs11555435; rs11555431; rs11555432; rs12881616; rs11555433; rs11555436; rs34409589
  *AKT2*     S302G; R371H
  *BRAF*     G464R; F595L; G596R; L597S; L597R; L597Q; L597V; T599I; V600E; V600K; V600R; V600L; K601N; K601E; G464V
  *CDK*      R24C; R24H
  *EGFR*     R108K; S768I; V769_D770insASV; V769_D770insCV; D770_N771\>AGG; V769_D770insASV; V769_D770insASV; D770_N771insG; N771_P772\>SVDNR; P772_H773insV; H773\>NPY; H773_V774insNPH; H773_V774insPH; H773_V774insH; V774_C775insHV; T263P; T790M; L858R; L861Q; A289V; G598V; E709K; E709H; E709A; E709G; E709V; G719S; G719C; G719A; M766_A767insAI; E746_T751del; E746_A750del; E746_A750del; E746_T751del; E746_A750del; E746_T751del; S752D; L747_E749del; L747_T750del; L747_S752del; L747_T751del; L747_S752del; P753S; L747_T751del; A750P; T751A; T751P; T751I; S752I/F; L747_Qins; E746_T751del; Iins; E746_A750del; T751A; E746_T751del; Vins; E746_A750del; Vins; L747_E749del; A750P; L747_T750del; Pins; L747_S752del; Qins; T751; S752_I759del
  *ERBB2*    L755P; G776S; G776LC; G776VC; A775_G776insYVMA; P780_Y781insGSP; P780_Y781insGSP; S779_P780insVGS
  *FGFR1*    S125L; P252T
  *FGFR3*    G370C; Y373C; A391E; K650Q; K650E; K650T; K650M
  *FLT3*     I836del; D835H; D835Y
  *HRAS*     G12V; G12D; G13C; G13R; G13S; Q61H; Q61H; Q61L; Q61R; Q61P; Q61K
  *JAK2*     V617F
  *KIT*      D52N; V559del; V559_V560del; V560del; P551_V555del; Y553_Q556del; Y570_L576del; E561K; L576P; P585P; D579del; Y503_F504insAY; K642E; D816V; D816H; D816Y; V825A; E839K; M552L; Y568D; F584S; W557R; W557R; W557G; V559D; V559A; V559G; V559I; V560D; V560G; K550_K558del; K558_V560del; K558_E562del
  *KRAS*     G12V; G12A; G12D; G12C; G12S; G12R; G12F; G13V; G13D; A59T; Q61E; Q61K; Q61L; Q61R; Q61P; Q61H; Q61H
  *MET*      R970C; T992I; Y1230C; Y1235D; M1250
  *NRAS*     G12V; G12A; G12D; G12C; G12R; G12S; G13V; G13A; G13D; G13C; G13R; G13S; A18T; Q61L; Q61R; Q61P; Q61H; Q61E; Q61K
  *PDGFRA*   V561D; I843_S847\>T; D842V; T674I; F808L; D846Y; N870S; D1071N; D842_H845del; I843_D846del; S566_E571\>K
  *PIK3CA*   R88Q; H1047Y; R38H; C901F; M1043I; M1043I; N345K; C420R; P539R; E542K; E545K; Q546K; H701P; H1047R; H1047L
  *RET*      C634R; C634W; C634Y; E632_L633del; M918T; A664D

###### 

Tests of between-subjects effects

  Source                                Type III sum of squares   *df*    Mean square    *F*     *P*-value
  ------------------------------------- ------------------------- ------- -------------- ------- -----------
  Corrected model                       6.784^a^                  20      0.339          1.777   0.033
  6.318                                 1                         6.318   33.087         0.000   
  Sex                                   0.024                     1       0.024          0.128   0.721
  Mutation                              1.250                     1       1.250          6.544   0.012
  Age                                   0.012                     1       0.012          0.065   0.799
  WHO                                   0.258                     1       0.258          1.351   0.248
  Clinical staging                      0.003                     1       0.003          0.018   0.893
  Sex \* mutation                       3.536×10^−5^              1       3.536×10^−5^   0.000   0.989
  Sex \* age                            0.284                     1       0.284          1.486   0.226
  Sex \* WHO                            0.031                     1       0.031          0.165   0.686
  Sex \* clinical staging               0.053                     1       0.053          0.276   0.600
  Mutation \* age                       0.251                     1       0.251          1.316   0.254
  Mutation \* WHO                       0.012                     1       0.012          0.065   0.800
  Mutation \* clinical staging          0.473                     1       0.473          2.475   0.119
  Age \* WHO                            0.414                     1       0.414          2.168   0.144
  Age \* clinical staging               0.027                     1       0.027          0.141   0.708
  WHO \* clinical staging               0.307                     1       0.307          1.607   0.208
  Sex \* mutation \* age                0.000                     0       --             --      --
  Sex \* mutation \* WHO                0.000                     0       --             --      --
  Sex \* mutation \* clinical staging   0.000                     0       --             --      --
  Sex \* age \* WHO                     0.462                     1       0.462          2.419   0.123
  Sex \* age \* clinical staging        2.665×10^−5^              1       2.665×10^−5^   0.000   0.991
  Sex \* WHO \* clinical staging        0.037                     1       0.037          0.195   0.660
  Mutation \* age \* WHO                0.000                     0       --             --      --
  Mutation \* age \* clinical staging   0.000                     0       --             --      --
  Mutation \* WHO \* clinical staging   0.000                     0       --             --      --
  Age \* WHO \* clinical staging        0.000                     0       --             --      --
  Sex \* mutation \* age \* WHO         0.000                     0       --             --      --
  Sex \* mutation \* age \*             0.000                     0       --             --      --
  Clinical staging                                                                               
  Sex \* mutation \* WHO \*             0.000                     0       --             --      --
  Clinical staging                                                                               
  Sex \* age \* WHO \*                  0.000                     0       --             --      --
  Clinical staging                                                                               
  Mutation \* age \* WHO \*             0.000                     0       --             --      --
  Clinical staging                                                                               
  Sex \* mutation \* age \*             0.000                     0       --             --      --
  WHO \* clinical staging                                                                        
  Error                                 19.476                    102     0.191                  
  Total                                 38.000                    123                            
  Corrected total                       26.260                    122                            

**Note:** Dependent variable: relapse/metastasis.

**Abbreviation:** WHO, World Health Organization.

###### 

Correlations between PIK3CA, NRAS, KIT mutations and clinicopathological characteristics of NPC patients

  Characteristics                   PIK3CA   NRAS   KIT                              
  --------------------------------- -------- ------ ------- --- --- ------- --- ---- -------
  Age (years)                                       1.000           1.000            1.000
   \<46                             3        47             2   4           2   47   
   ≥46                              3        55             3   5           2   55   
  Sex                                               0.334           1.000            1.000
   Male                             6        78             4   7           3   78   
   Female                           0        24             1   2           1   24   
  Clinical stage                                    0.333           0.611            1.000
   I+II                             0        27             2   2           1   27   
   III+IV                           6        75             3   7           3   75   
  Relapse/metastasis                                0.333           0.611            0.068
   No                               6        75             3   7           1   75   
   Yes                              0        27             2   2           3   27   
  WHO histological classification                   0.587           1.000            0.147
   NKUC                             6        85             4   8           2   85   
   NKDC                             0        17             1   1           2   17   
   KSCC                             0        0              0   0           0   0    

**Abbreviations:** NPC, nasopharyngeal carcinoma; WHO, World Health Organization; NKUC, non-keratinizing undifferentiated carcinoma; NKDC, non-keratinizing differentiated carcinoma; KSCC, keratinizing squamous cell carcinoma.
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![Representative graphs showing the mutations detected by time-of-flight mass spectrometry using *NRAS*-8. (**A**) Blank control. Only a peak representing the uncombined probe is apparent, with no sample peaks. (**B**) Negative control. A peak for the negative sample is shown, with no mutation peak or close chemical noise peak. However, there is a clear standard peak for the wild-type sample. (**C**) A typical mutation peak. The wild-type peak and a mutation peak are apparent, with no abnormality noted in the blank control (**A**) or negative control (**B**).](ott-7-457Fig1){#f1-ott-7-457}

![Kaplan--Meier survival curves for NPC patients. (**A**) Overall survival (OS) of the NPC patients with oncogene mutations vs that of wild-type patients. (**B**) Progression-free survival (PFS) of NPC patients with oncogene mutations vs that of wild-type patients.](ott-7-457Fig2){#f2-ott-7-457}

###### 

Clinical characteristics of 123 NPC patients

  Characteristic                       Number of patients
  ------------------------------------ --------------------
  Sex                                  
   Male                                95 (77.2%)
   Female                              28 (22.8%)
  Age (years)                          
   Median                              46
   ≤46                                 66
   \>46                                57
  Overall survival (months)            
   Median                              57
   Range                               6--120
  Progression-free survival (months)   
   Median                              52
   Range                               5--118
  Clinical stage                       
   I+II                                32 (26.0%)
   III+IV                              91 (74.0%)
  Relapse/metastasis                   
   No                                  86 (69.9%)
   Yes                                 37 (30.1%)
  Therapeutic modality                 
   No treatment                        17 (13.8%)
   Radiotherapy alone                  83 (67.5%)
   Chemotherapy alone                  1 (0.8%)
   Radiochemotherapy                   22 (17.9%)
  WHO histological classification      
   NKUC                                101 (82.1%)
   NKDC                                22 (17.9%)
   KSCC                                0 (0%)

**Abbreviations:** NPC, nasopharyngeal carcinoma; WHO, World Health Organization; NKUC, non-keratinizing undifferentiated carcinoma; NKDC, non-keratinizing differentiated carcinoma; KSCC, keratinizing squamous cell carcinoma.

###### 

Mutation status of the 21 positive cases

  Sample ID   Gene       Mutation   Ratio   
  ----------- ---------- ---------- ------- ------
  NPC053      *PIK3CA*   R38H       0.07    0.93
  NPC125      *PIK3CA*   H1047Y     0.07    0.93
  NPC064      *PIK3CA*   H1047Y     0.08    0.92
  NPC041      *PIK3CA*   E542K      0.07    0.93
  NPC113      *PIK3CA*   E542K      0.21    0.79
  NPC029      *PIK3CA*   E545K      0.05    0.95
  *BRAF*      G464E      0.18       0.82    
  NPC056      *PDGFRA*   T674I      0.10    0.90
  NPC087      *PDGFRA*   T674I      0.10    0.90
  NPC093      *NRAS*     G12D       0.12    0.88
  NPC042      *NRAS*     G13D       0.10    0.90
  NPC050      *NRAS*     G13D       0.11    0.89
  NPC022      *NRAS*     Q61K       0.14    0.86
  NPC044      *NRAS*     Q61K       0.21    0.79
  NPC021      *KIT*      D52N       0.10    0.90
  NPC120      *KIT*      V559A      0.29    0.71
  NPC099      *KIT*      V559I      0.16    0.84
  NPC121      *KIT*      V559I      0.22    0.78
  NPC030      *ABL*      E255K      0.14    0.86
  NPC038      *ABL*      E255K      0.13    0.87
  NPC019      *EGFR*     E709A      0.14    0.86
  NPC031      *HRAS*     G13S       0.08    0.92

**Abbreviations:** WT, wild-type; MT, mutation.

###### 

Correlations between oncogene mutation and clinicopathological characteristics of NPC patients

  Characteristics                   Mutation n=21 (17.1%)   Wild-type n=102 (82.9%)   *P*-value
  --------------------------------- ----------------------- ------------------------- -----------
  Age (years)                                                                         0.359
   \<46                             12 (20.3%)              47 (79.7%)                
   ≥46                              9 (14.1%)               55 (85.9%)                
  Sex                                                                                 0.656
   Male                             17 (17.9%)              78 (82.1%)                
   Female                           4 (14.3%)               24 (85.7%)                
  Clinical stage                                                                      0.800
   I+II                             5 (15.6%)               27 (84.4%)                
   III+IV                           16 (17.6%)              75 (82.4%)                
  Relapse/metastasis                                                                  0.019
   No                               10 (11.8%)              75 (88.2%)                
   Yes                              11 (28.9%)              27 (71.1%)                
  WHO histological classification                                                     0.437
   NKUC                             16 (15.8%)              85 (84.2%)                
   NKDC                             5 (22.7%)               17 (77.3%)                
   KSCC                             0 (0%)                  0 (0%)                    

**Abbreviations:** NPC, nasopharyngeal carcinoma; WHO, World Health Organization; NKUC, non-keratinizing undifferentiated carcinoma; NKDC, non-keratinizing differentiated carcinoma; KSCC, keratinizing squamous cell carcinoma.

###### 

Summary of oncogene mutations in NPC

  Gene       Mutation status in this study   Mutation status in other NPC studies                                                                                                                                                      More NPC literature
  ---------- ------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------
  *ABL1*     1.6% (2 of 123)                 No report                                                                                                                                                                                 No report
  *AKT1*     0%                              No report                                                                                                                                                                                 No report
  *AKT2*     0%                              No report                                                                                                                                                                                 No report
  *BRAF*     0.8% (1 of 123)                 0% (0 of 65) (sequencing)[@b33-ott-7-457]                                                                                                                                                 No report
  *CDK4*     0%                              No report                                                                                                                                                                                 Expression of mRNA and protein(RT-PCR and IHC)[@b22-ott-7-457]
  *EGFR*     0.8% (1 of 123)                 0% (0 of 60) (sequencing)[@b23-ott-7-457]; 0% (0 of 102) (sequencing)[@b24-ott-7-457]                                                                                                     Expression rate 65.6% (IHC)[@b25-ott-7-457]; expression rate 70.9% (IHC)[@b26-ott-7-457]
  *ERBB2*    0%                              No report                                                                                                                                                                                 Expression rate 37.5% (IHC)[@b25-ott-7-457]; amplification rate 43.3% (C-PCR)[@b27-ott-7-457]
  *FGFR1*    0%                              No report                                                                                                                                                                                 No report
  *FGFR3*    0%                              No report                                                                                                                                                                                 No report
  *FLT3*     0%                              No report                                                                                                                                                                                 No report
  *HRAS*     0.8% (1 of 123)                 No report                                                                                                                                                                                 No report
  *KRAS*     0%                              0% (0 of 45) (sequencing)[@b33-ott-7-457]; no mutation in 4 NPC cell lines (sequencing)[@b28-ott-7-457]                                                                                   No report
  *NRAS*     4.1% (5 of 123)                 No report                                                                                                                                                                                 Amplification (CGH)[@b25-ott-7-457]
  *JAK2*     0%                              No report                                                                                                                                                                                 No report
  *MET*      0%                              No report                                                                                                                                                                                 No expression (IHC)[@b29-ott-7-457]; expression rate 91.1% (IHC)[@b30-ott-7-457]
  *KIT*      3.3% (4 of 123)                 5 cell lines reported intron mutation (sequencing)[@b18-ott-7-457]                                                                                                                        No report
  *PDGFRA*   1.6% (2 of 123)                 No report                                                                                                                                                                                 No report
  *PIK3CA*   4.9% (6 of 123)                 4.3% (2 of 46) (clone sequencing)[@b17-ott-7-457]; 0% (0 of 27) (sequencing)[@b32-ott-7-457]; 9.6% (7 of 73) (sequencing)[@b33-ott-7-457]; 1.13% (1 of 88) (sequencing)[@b31-ott-7-457]   21.6% amplification (RT-PCR)[@b31-ott-7-457]
  *RET*      0%                              No report                                                                                                                                                                                 No report

**Abbreviations:** CGH, comparative genomic hybridization; IHC, immunohistochemistry; NPC, nasopharyngeal carcinoma; RT-PCR, real-time polymerase chain reaction; C-PCR, competitive polymerase chain reaction; mRNA, messenger RNA.

[^1]: \*These authors contributed equally to this work
